Bilcare Ltd
Incorporated in 1987, Bilcare Ltd. is engaged in the business of Pharmaceutical Packaging, Global Clinical Services, R&D services and Anti Counterfeit Technology (nCid).
- Market Cap ₹ 188 Cr.
- Current Price ₹ 79.9
- High / Low ₹ 98.0 / 51.0
- Stock P/E
- Book Value ₹ 199
- Dividend Yield 0.00 %
- ROCE 1.29 %
- ROE -5.31 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.40 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -15.5% over past five years.
- Promoter holding is low: 30.0%
- Company has a low return on equity of -5.21% over last 3 years.
- Contingent liabilities of Rs.721 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
3,062 | 2,692 | 2,603 | 2,633 | 2,778 | 2,997 | 1,827 | 623 | 845 | 982 | 747 | 788 | |
2,819 | 2,506 | 2,396 | 2,443 | 2,617 | 2,827 | 1,782 | 572 | 784 | 925 | 708 | 743 | |
Operating Profit | 243 | 186 | 207 | 190 | 161 | 170 | 45 | 51 | 60 | 57 | 39 | 45 |
OPM % | 8% | 7% | 8% | 7% | 6% | 6% | 2% | 8% | 7% | 6% | 5% | 6% |
24 | 9 | -87 | 107 | 297 | 59 | 254 | 45 | 44 | 237 | 16 | 12 | |
Interest | 217 | 236 | 151 | 176 | 249 | 283 | 174 | 76 | 69 | 60 | 82 | 82 |
Depreciation | 141 | 191 | 164 | 177 | 416 | 378 | 239 | 46 | 39 | 38 | 45 | 46 |
Profit before tax | -91 | -232 | -194 | -56 | -207 | -433 | -114 | -25 | -4 | 196 | -72 | -71 |
Tax % | 25% | -7% | -58% | 42% | -4% | 5% | -13% | -55% | 3% | 74% | -18% | -21% |
-114 | -216 | -82 | -80 | -199 | -453 | -99 | -11 | -4 | 50 | -59 | -56 | |
EPS in Rs | -48.14 | -91.76 | -36.04 | -35.91 | -85.43 | -193.28 | -43.97 | -8.95 | -5.35 | 6.39 | -14.12 | -12.22 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -12% |
5 Years: | -15% |
3 Years: | -2% |
TTM: | 5% |
Compounded Profit Growth | |
---|---|
10 Years: | 6% |
5 Years: | 14% |
3 Years: | 8% |
TTM: | 21% |
Stock Price CAGR | |
---|---|
10 Years: | 6% |
5 Years: | 16% |
3 Years: | 5% |
1 Year: | 37% |
Return on Equity | |
---|---|
10 Years: | -38% |
5 Years: | -9% |
3 Years: | -5% |
Last Year: | -5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
Reserves | 1,300 | 1,073 | 689 | 590 | 376 | -93 | 85 | 63 | 52 | 507 | 474 | 445 |
2,146 | 2,311 | 2,122 | 2,014 | 2,089 | 2,270 | 707 | 677 | 690 | 639 | 756 | 682 | |
899 | 933 | 786 | 830 | 913 | 888 | 297 | 300 | 362 | 424 | 314 | 266 | |
Total Liabilities | 4,368 | 4,340 | 3,620 | 3,457 | 3,402 | 3,087 | 1,112 | 1,064 | 1,127 | 1,593 | 1,568 | 1,417 |
2,126 | 1,926 | 2,432 | 2,403 | 2,180 | 2,005 | 534 | 494 | 465 | 1,045 | 1,038 | 950 | |
CWIP | 262 | 218 | 161 | 149 | 170 | 79 | 0 | 0 | 1 | 1 | 1 | 3 |
Investments | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 8 | 11 |
1,979 | 2,196 | 1,026 | 904 | 1,051 | 1,003 | 577 | 570 | 661 | 545 | 521 | 453 | |
Total Assets | 4,368 | 4,340 | 3,620 | 3,457 | 3,402 | 3,087 | 1,112 | 1,064 | 1,127 | 1,593 | 1,568 | 1,417 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
314 | -315 | 177 | 300 | 98 | 206 | 256 | 72 | 41 | -7 | 62 | 85 | |
-351 | 247 | -358 | -129 | -203 | -104 | 1,309 | 2 | -4 | 36 | -106 | 81 | |
48 | 119 | 149 | -155 | 91 | -103 | -1,600 | -83 | -55 | -19 | 36 | -169 | |
Net Cash Flow | 12 | 50 | -32 | 16 | -13 | -1 | -35 | -9 | -18 | 10 | -7 | -3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 105 | 125 | 35 | 29 | 38 | 38 | 22 | 90 | 95 | 70 | 73 | 55 |
Inventory Days | 103 | 105 | 108 | 84 | 90 | 82 | 28 | 90 | 83 | 42 | 77 | 80 |
Days Payable | 76 | 93 | 86 | 81 | 102 | 71 | 35 | 93 | 102 | 77 | 70 | 57 |
Cash Conversion Cycle | 132 | 137 | 57 | 32 | 25 | 49 | 15 | 88 | 76 | 34 | 80 | 78 |
Working Capital Days | 145 | 156 | 35 | 16 | 24 | 28 | 27 | 67 | 57 | 36 | 115 | 96 |
ROCE % | 3% | 1% | 2% | 2% | -8% | -6% | -9% | 3% | 3% | 3% | 1% | 1% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Bilcare's revised secretarial compliance report for FY 2024-25 with minor filing delays, no major issues.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Bilcare's revised secretarial compliance report for FY2025 with minor filing delays, no major issues.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 30 May
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Bilcare's Annual Secretarial Compliance Report for FY 2024-25 with minor filing delays, no major non-compliance.
-
Integrated Filing (Financial)
29 May - Bilcare reports FY25 audited results; standalone profit turnaround; consolidated loss; 75 Cr asset sale; ongoing SFIO probe noted.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Products & Services offered:
a) Pharma Packaging:[1]
Pharma Packaging is available in two broad categories viz., Polymer based Packaging Films and Aluminum based Packaging Foils. Their sub-categories are:
Blister Films
Blister Foils
Lidding Foils
CR Foils
Laminates
b) Global Clinical Supplies and Services:[2]
Company handles domestic and global manufacturing of IMPs and Placebos, Primary
and secondary packaging with various blinding techniques, IWRS, Storage at variable temperatures.